 This study found that biologic therapy significantly reduced disease-related quality of life, DLQI, scores in patients with moderate to severe chronic plaque psoriasis, with Illinois, 12, 23 blockades showing the greatest reduction. Other therapies, including etinosept and all systemic agents, did not show significant change. The study also identified significant predictors of lack of reduction in DLQI score, including a baseline posi score less than 16 in history of diabetes, alcoholism or uveitis. This article was authored by Diana Norris, Louise Fosher, Mark Tacey, and others.